Serum lipid profile

New evidence indicates that lower doses of estrogens are effective in controlling postmenopausal symptoms and reducing bone loss (see Table 31-2). Even ultralow doses of 17 /J-estradiol delivered by vaginal ring improved serum lipid profiles and prevented bone loss in elderly women. 

Draper MW, Flowers DE, Huster WJ, et al. (1996) A controlled trial of Raloxifene (LY 139481) HC1 impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11 835-842... 

Only one study thus far has evaluated the effect of CCM fortification of the diet on serum lipid profiles. It was a randomized, single-blind, crossover metabolic diet study with two 10-day periods separated by a 10-day washout (Denke et al, 1993). The subjects included 13 healthy men (mean SD 43 4 years) classified as moderately hypercholesterolemic (mean SD 6.19 0.37 mmol serum cholesterol at baseline) and with a low baseline Ca intake (mean SD 466 199 mg Ca/day). The low-Ca basal diet contained 34% energy from fat (primarily as beef tallow), 13% from saturated fat, 240 mg cholesterol/day, and 410 mg Ca/day. The high-Ca diet was similar in composition except that CCM... 

Yalcin, E., Hassanzadeh, A., and Mawlud, K. (1997) The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr Jpn 39 342-345. 

Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer a companion study to EORTC Trial 10951, Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients . Ann Oncol 2004 15(2) 211—7. 

Itoi H, Minakami H, Iwasaki R, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas 2000 36(3) 217-22. 

In clinical practice, depressive symptoms were common in patients with physical illness, including cardiovascular disease, diabetes mellitus, end-stage renal disease, and women in pregnancy, following delivery or menopause. However, data that specifically addressed serum lipid profiles in patients with depressive disorders and physical illnesses were still scarce. 

In this review we discuss the relationships between serum lipid profile levels, major depression, and suicide attempts, as well as the interactions between lipid profiles, stress, HPA axis, and inflammation/immunity in depressive disorders. The conclusion emphasizes the importance of integrated data between clinical phenotypes and molecular mechanisms in depressive disorders. 

Laboratory studies indicated that her fasting serum glucose level was 85 mg/dL (normal is less than 100). Her serum lipid profile was within the normal range total cholesterol 168 mg/dL HDL cholesterol 43 mg/dL LDL... 

The antiatherosclerotic effect of proanthocyanidin-rich grape seed extracts was examined in cholesterol-fed rabbits. The proanthocyanidin-rich extracts [0.1% and 1% in diets (w/w)] did not change the serum lipid profile, but reduced the level of the cholesteryl ester hydroperoxides (ChE-OOH) induced by 2,2/-azo-bis(2-amidinopropane-dihydrochloride (AAPH), the aortic malonaldehyde (MDA) content and severe atherosclerosis. The immuno-histochemical analysis revealed a decrease in the number of the oxidized LDL-positive macrophage-derived foam cells on the atherosclerotic lesions of the aorta in the rabbits fed the proanthocyanidin-rich extract. When the proanthocyanidin-rich extract was administered orally to the rats, proantho-cyanidin was detected in the plasma. In an in vitro experiment using human plasma, the addition of the proanthocyanidin-rich extract to the plasma inhibited the oxidation of cholesteryl linoleate in the LDL, but not in the LDL isolated after the plasma and the extract were incubated in advance. From these results, proanthocyanidins of the major polyphenols in red wine might trap ROSs in the plasma and interstitial fluid of the arterial wall, and consequently display antiatherosclerotic activity by inhibiting the oxidation of the LDL [92]. 

Epidemiological findings show that pecan-enriched diets can favorably alter serum lipid profiles in humans and thus reduce cardiovascular disease risk (38) however, the effects of pecan oil intake on human blood lipid profiles have not been reported. 

Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by unltra-low doses of 17jS-estradiol in elderly women. J Qin Endocrinol Metab 2001 86 2757-2762. 

Changes in serum lipid profiles commonly occurred in rats exposed to PCBs in intermediate-duration dietary studies (Andrews 1989 Bruckner et al. 1974, 1977 Gray et al. 1993 Kato et al. 1981a, 1981b, 1982b Kling and Gamble 1982 Litters et al. 1972). Effects included increased liver lipids at... 

An aberrant serum lipid profile is associated with increased risk of artherosderosis and cardiac heart disease. 

In general, beta-receptor antagonists have a detrimental effect on the serum lipid profile. Triglyceride levels are sharply increased, as are low-density lipoproteins (LDL) levels, while high-density lipoproteins (HDL) levels may be decreased. This effect is lessened, or even reversed, with drugs that have intrinsic sympathomimetic activity (e.g., pindolol, acebutolol). 

What effect does metformin have on the serum lipid profile ... 

Receptor antagonists can reduce activation of hormone-sensitive lipase and attenuate the release of free fatty acids from adipose tissue. Nonselective /3 receptor antagonists consistently reduce HDL cholesterol, increase LDL cholesterol, and increase triglycerides. In contrast, fi -selective antagonists improve the serum lipid profile of dyslipidemic patients. Propranolol and atenolol increase triglycerides, whereas chronic celiprolol, carvedilol, and carteolol reduce plasma triglycerides. 

Treatment of FCH includes restriction of dietary fat. Patients who do not respond adequately to dietary therapy are treated with antilipidemic drugs. Selection of the appropriate antilipidemic drugs depends on the specific phenotypic expression of the patient s multigenic disease as manifest by their particular serum lipid profile. In Cora s case, a decrease in both serum triacylglycerols and LDL cholesterol must be achieved. If possible, her serum HDL cholesterol level should also be raised to a level above 40 mg/dL. 

Serum Lipid Levels. Several reports described changes in the serum lipid profile of humans exposed to zinc suifate or gluconate for 3-12 months however, the results are mixed. Ingestion of 2.3-4.3 mg zinc/kg/day for 5-6 weeks (Chandra 1984 Hooper et al. 1980) or 0.71 mg zinc/kg/day for 12 weeks (Black et al. 1988) reduced levels of high-density lipoprotein (HDL) cholesterol. In the study by Chandra (1984), a slight increase in low-density lipoprotein (LDL) cholesterol was observed in... 

---